These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9547132)

  • 21. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
    Kronig MH; Apter J; Asnis G; Bystritsky A; Curtis G; Ferguson J; Landbloom R; Munjack D; Riesenberg R; Robinson D; Roy-Byrne P; Phillips K; Du Pont IJ
    J Clin Psychopharmacol; 1999 Apr; 19(2):172-6. PubMed ID: 10211919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
    Bennie EH; Mullin JM; Martindale JJ
    J Clin Psychiatry; 1995 Jun; 56(6):229-37. PubMed ID: 7775364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
    Jenike MA; Baer L; Summergrad P; Minichiello WE; Holland A; Seymour R
    Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
    Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do soft signs predict treatment outcome in obsessive-compulsive disorder?
    Thienemann M; Koran LM
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):218-22. PubMed ID: 7626966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Response to sertraline in adolescents with obsessive-compulsive disorder].
    Rodríguez-Ramos P; Mardomingo Sanz MJ
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(1):17-21. PubMed ID: 9549132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
    Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
    Mowla A; Modarresi F; Dastgheib SA
    Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
    Aguglia E; Casacchia M; Cassano GB; Faravelli C; Ferrari G; Giordano P; Pancheri P; Ravizza L; Trabucchi M; Bolino F
    Int Clin Psychopharmacol; 1993; 8(3):197-202. PubMed ID: 8263318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder.
    Fineberg NA; Baldwin DS; Drummond LM; Wyatt S; Hanson J; Gopi S; Kaur S; Reid J; Marwah V; Sachdev RA; Pampaloni I; Shahper S; Varlakova Y; Mpavaenda D; Manson C; O'Leary C; Irvine K; Monji-Patel D; Shodunke A; Dyer T; Dymond A; Barton G; Wellsted D
    Int Clin Psychopharmacol; 2018 Nov; 33(6):334-348. PubMed ID: 30113928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
    Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
    J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insight and treatment outcome in obsessive-compulsive disorder.
    Eisen JL; Rasmussen SA; Phillips KA; Price LH; Davidson J; Lydiard RB; Ninan P; Piggott T
    Compr Psychiatry; 2001; 42(6):494-7. PubMed ID: 11704942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.